An Important Parameters of Aminoglycosides
Abstract
Despite being an older class of drugs, aminoglycosides are nevertheless useful in clinical settings. A wide range of aerobic species, including gram-negative bacteria and mycobacteria, are affected by aminoglycosides. Gentamicin, tobramycin, amikacin, neomycin, plazomicin, and streptomycin are among the medications in the aminoglycoside class; the FDA has approved different indications for each of these treatments. For members of the interprofessional team who want to prescribe aminoglycosides, this activity explains the indications, contraindications, mechanism of action, adverse event profile, and other important factors (e.g., off label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions).
References
Avent, M. L., Rogers, B. A., Cheng, A. C., & Paterson, D. L. (2011). Current use of aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity. Internal Medicine Journal, 41(6), 441–449.
Pagkalis, S., Mantadakis, E., Mavros, M. N., Ammari, C., & Falagas, M. E. (2011). Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs, 71(17), 2277–2294.
Kotra, L. P., Haddad, J., & Mobashery, S. (2000). Aminoglycosides: Perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrobial Agents and Chemotherapy, 44(12), 3249–3256.
Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016). Aminoglycosides: An overview. Cold Spring Harbor Perspectives in Medicine, 6(6).
Smith, S., Rowbotham, N. J., & Charbek, E. (2018). Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database of Systematic Reviews, 2018(10), Article CD008319.
Ranganathan, D., Varghese, J. M., Fassett, R. G., Lipman, J., D'Intini, V., Healy, H., & Roberts, J. A. (2009). Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. BMC Nephrology, 10, Article 42.
LeBras, M., Chow, I., Mabasa, V. H., & Ensom, M. H. (2016). Systematic review of efficacy, pharmacokinetics, and administration of intraventricular aminoglycosides in adults. Neurocritical Care, 25(3), 492–507.
Leis, J. A., Rutka, J. A., & Gold, W. L. (2015). Aminoglycoside-induced ototoxicity. CMAJ, 187(1), E52.
Selimoglu, E. (2007). Aminoglycoside-induced ototoxicity. Current Pharmaceutical Design, 13(1), 119–126.
Guthrie, O. W. (2008). Aminoglycoside induced ototoxicity. Toxicology, 249(2–3), 91–96.
Wargo, K. A., & Edwards, J. D. (2014). Aminoglycoside-induced nephrotoxicity. Journal of Pharmacy Practice, 27(6), 573–577.
Lopez-Novoa, J. M., Quiros, Y., Vicente, L., Morales, A. I., & Lopez-Hernandez, F. J. (2011). New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view. Kidney International, 79(1), 33–45.
Del Pozo, E., & Baeyens, J. M. (1986). Effects of calcium channel blockers on neuromuscular blockade induced by aminoglycoside antibiotics. European Journal of Pharmacology, 128(1–2), 49–54.
Barrons, R. W. (1997). Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy, 17(6), 1220–1232.
Roberts, J. A., Norris, R., Paterson, D. L., & Martin, J. H. (2012). Therapeutic drug monitoring of antimicrobials. British Journal of Clinical Pharmacology, 73(1), 27–36.
Vural, A., Koçyiğit, İ., Şan, F., Eroğlu, E., Ketenci, İ., Ünal, A., Tokgöz, B., & Ünlü, Y. (2018). Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: A randomized trial. Peritoneal Dialysis International, 38(1), 57–62.
Refbacks
- There are currently no refbacks.